This week, we will be discussing a randomized controlled trial of eculizumab in STEC-HUS. Will eculizumab manage to surpass its well-established reputation as expensivumab and demonstrate some positive results?
CHIPping away at Kidney Disease
Nephrin in Nephrotic Syndrome
Nephrology Fellowship and COVID-19
Minimal Role for Steroids in Minimal Change Disease?
Are ANCA actually attackers?
Nephrology Research. Are we improving?
MesoAmerican Nephropathy: More Light on the Heat Hypothesis?
Antibiotics are bad, the Stone Edition
Nephrocystin: More Notable than we thought?
To most Nephrologists, Nephronophthisis (NPH) is considered to be a rare autosomal recessive paediatric disease. However, this article by Snoek et al challenges that belief, by examining the prevalence of mutations that cause NPH, in adults with end stage renal disease (ESRD). Read our NephJC summary below and come along to our Twitter Journal Club discussion to find out whether you might consider a diagnosis of NPH, next time you see that patient carrying a label of ‘ESRD, cause unknown’.
Longer HD, but no change in QoL, the wrap up
ACTIVE trial, the Visual Abstract
The Visual Abstract for the ACTIVE trial NephJC, scheduled for Tuesday/Wednesday this week. From the Visual Abstract artist, @KidneyBea_n
Longer is Better, Except when it is Not, Really: Hemodialysis Edition
The Avacopan wrapup
Marking the debut of Cathy Quinlan, hosting from down under!
Avacopan in ANCA-Associated Vasculitis
#NephJC contrast wrap up
We missed posting the wrap up on this one!
Here are the transcripts
